Search

Your search keyword '"Colombo, Stefania"' showing total 14 results
Start Over Author "Colombo, Stefania"
14 results on '"Colombo, Stefania"'

5. Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry

Author

Ammirati, Enrico, Cipriani, Manlio, Moro, Claudio, Raineri, Claudia, Pini, Daniela, Sormani, Paola, Mantovani, Riccardo, Varrenti, Marisa, Pedrotti, Patrizia, Conca, Cristina, Mafrici, Antonio, Grosu, Aurelia, Briguglia, Daniele, Guglielmetto, Silvia, Perego, Giovanni B., Colombo, Stefania, Caico, Salvatore I., Giannattasio, Cristina, Maestroni, Alberto, Carubelli, Valentina, Metra, Marco, Lombardi, Carlo, Campodonico, Jeness, Agostoni, Piergiuseppe, Peretto, Giovanni, Scelsi, Laura, Turco, Annalisa, Di Tano, Giuseppe, Campana, Carlo, Belloni, Armando, Morandi, Fabrizio, Mortara, Andrea, Cirò, Antonio, Senni, Michele, Gavazzi, Antonello, Frigerio, Maria, Oliva, Fabrizio, Camici, Paolo G., Briani, Martina, Odello, Tania, Botti, Paolo, Bertelli, Erika, Apruzzese, Claudio, Spezzano, Tiziana, and Wu, Monica

Published
2018
Full Text
View/download PDF

6. Successful recovery from severe inverted Takotsubo cardiomyopathy after liver transplantation: the efficacy of extracorporeal membrane oxygenation (ECMO)

Author

LAUTERIO, Andrea, primary, BOTTIROLI, Maurizio, additional, CANNATA, Aldo, additional, DE CARLIS, Riccardo, additional, VALSECCHI, Mila, additional, PERRICONE, Giovanni, additional, COLOMBO, Stefania, additional, BUSCEMI, Vincenzo, additional, ZANIBONI, Matteo, additional, PEDRAZZINI, Giovanna, additional, MONDINO, Michele, additional, RUSSO, Claudio, additional, FUMAGALLI, Roberto, additional, and DE CARLIS, Luciano, additional

Published
2022
Full Text
View/download PDF

8. Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis

Author

Ammirati, Enrico, Cipriani, Manlio, Moro, Claudio, Raineri, Claudia, Pini, Daniela, Sormani, Paola, Mantovani, Riccardo, Varrenti, Marisa, Pedrotti, Patrizia, Conca, Cristina, Mafrici, Antonio, Grosu, Aurelia, Briguglia, Daniele, Guglielmetto, Silvia, Perego, Giovanni B, Colombo, Stefania, Caico, Salvatore I, Giannattasio, Cristina, Maestroni, Alberto, Carubelli, Valentina, Metra, Marco, Lombardi, Carlo, Campodonico, Jeness, Agostoni, Piergiuseppe, Peretto, Giovanni, Scelsi, Laura, Turco, Annalisa, Di Tano, Giuseppe, Campana, Carlo, Belloni, Armando, Morandi, Fabrizio, Mortara, Andrea, Cirò, Antonio, Senni, Michele, Gavazzi, Antonello, Frigerio, Maria, Oliva, Fabrizio, Camici, Paolo G, Ammirati, Enrico, Cipriani, Manlio, Moro, Claudio, Raineri, Claudia, Pini, Daniela, Sormani, Paola, Mantovani, Riccardo, Varrenti, Marisa, Pedrotti, Patrizia, Conca, Cristina, Mafrici, Antonio, Grosu, Aurelia, Briguglia, Daniele, Guglielmetto, Silvia, Perego, Giovanni B, Colombo, Stefania, Caico, Salvatore I, Giannattasio, Cristina, Maestroni, Alberto, Carubelli, Valentina, Metra, Marco, Lombardi, Carlo, Campodonico, Jene, Agostoni, Piergiuseppe, Peretto, Giovanni, Scelsi, Laura, Turco, Annalisa, Di Tano, Giuseppe, Campana, Carlo, Belloni, Armando, Morandi, Fabrizio, Mortara, Andrea, Cirò, Antonio, Senni, Michele, Gavazzi, Antonello, Frigerio, Maria, Oliva, Fabrizio, and Camici, Paolo G

Subjects
myocarditi, treatment outcome, magnetic resonance imaging, biopsy, heart transplantation
Abstract

There is controversy about the outcome of patients with acute myocarditis (AM), and data are lacking on how patients admitted with suspected AM are managed. We report characteristics, in-hospital management, and long-term outcome of patients with AM based on a retrospective multicenter registry from 19 Italian hospitals.

Published
2019

11. Tumor Necrosis Factorα, Interleukin 2, and Soluble Interleukin 2 Receptor Levels in Human Immunodeficiency Virus Type 1-Infected Individuals Receiving Intermittent Cycles of Interleukin 2

Author

Fortis, Claudio, primary, Soldini, Laura, additional, Ghezzi, Silvia, additional, Colombo, Stefania, additional, Tambussi, Giuseppe, additional, Vicenzi, Elisa, additional, Gianotti, Nicola, additional, Nozza, Silvia, additional, Veglia, Fabrizio, additional, Murone, Michelangelo, additional, Lazzarin, Adriano, additional, and Poli, Guido, additional

Published
2002
Full Text
View/download PDF

12. Tumor Necrosis Factor α, Interleukin 2, and Soluble Interleukin 2 Receptor Levels in Human Immunodeficiency Virus Type 1-Infected Individuals Receiving Intermittent Cycles of Interleukin 2

Author

Fortis, Claudio, Soldini, Laura, Ghezzi, Silvia, Colombo, Stefania, Tambussi, Giuseppe, Vicenzi, Elisa, Gianotti, Nicola, Nozza, Silvia, Veglia, Fabrizio, Murone, Michelangelo, Lazzarin, Adriano, and Poli, Guido

Abstract

HIV-infected individuals with 200-500 CD4+ T cell/μl were enrolled in a controlled study of three interleukin 2 (IL-2) plus antiretroviral therapy (ART) regimens: (1) continuous intravenous administration of 12 million international units (MIU) of IL-2 followed by subcutaneous high-dose IL-2 (7.5 MIU, twice daily) for 5 days every 8 weeks; (2) high-dose subcutaneous IL-2 for 5 days every 8 weeks; (3) low-dose (3 MIU, twice daily) subcutaneous IL-2 for 5 days every 4 weeks; and (4) ART alone. Serum concentrations of IL-2, soluble IL-2 receptor (sIL-2R), tumor necrosis factor α (TNF-α), and IL-6 were determined. A progressive decrease over time of the circulating levels of IL-2 was observed in individuals receiving the highest doses of IL-2, but not in those belonging to the low-dose arm. Conversely, increased levels of sIL-2R were observed in all cytokine-treated individuals. The levels of TNF-α increased in the high-dose IL-2 regimens, but decreased in individuals receiving low-dose IL-2. IL-2-related toxicity was significantly correlated to the peak IL-2 serum levels, and was substantially lower in those individuals receiving low-dose IL-2. In conclusion, intermittent IL-2 administration causes the elevation of peripheral CD4+ T cells, but also a profound cytokine response and systemic toxicity. The latter was correlated to the peak serum level of IL-2, but not to those of TNF-α and IL-6.

Published
2002
Full Text
View/download PDF

13. Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study

Author

Emanuela Dell'Aquila, Chiara Carlomagno, Carmine Pinto, Giorgio Reggiardo, Domenico Corsi, Alfredo Colombo, Gerardo Rosati, Giuseppe Cicero, Domenico Bilancia, Antonio Avallone, Giuseppe Aprile, Stefania Rapisardi, Marika Cinausero, Silvia Brugnatelli, Rosati, Gerardo, Corsi, Domenico, Avallone, Antonio, Brugnatelli, Silvia, Dell'Aquila, Emanuela, Cinausero, Marika, Aprile, Giuseppe, Cicero, Giuseppe, Carlomagno, Chiara, Colombo, Alfredo, Rapisardi, Stefania, Pinto, Carmine, Reggiardo, Giorgio, Bilancia, Domenico, and Gerardo Rosati, Domenico Corsi, Antonio Avallone, Silvia Brugnatelli, Emanuela Dell'Aquila, Marika Cinausero, Giuseppe Aprile, Giuseppe Cicero, Chiara Carlomagno, Alfredo Colombo, Stefania Rapisardi, Carmine Pinto, Giorgio Reggiardo, Domenico Bilancia

Subjects
medicine.medical_specialty, Reduced dose, Colorectal cancer, Leucovorin, Cetuximab, Neutropenia, Gastroenterology, FOLFOX, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Panitumumab, Doublet chemotherapy, Anti-EGFR, Aged, Metastatic colorectal cancer, Rectal Neoplasms, business.industry, Anti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patients, Exanthema, medicine.disease, Rash, Vulnerable older patients, Oncology, Colonic Neoplasms, FOLFIRI, Fluorouracil, Geriatrics and Gerontology, medicine.symptom, Colorectal Neoplasms, business, medicine.drug
Abstract

Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres. The median age was 75 (range, 70–85). Geriatric screening by G8 tool gave a score ≤ 14 in all patients. In total, 75 and 43 patients received FOLFOX or FOLFIRI, respectively, in combination with panitumumab (53%) or cetuximab (47%). The overall incidence of grade (G) 3–4 neutropenia was 11.8%, and for skin rash 11%. The most frequent adverse events were G1–2 skin rash (49.1%), G1–2 diarrhea (21.1%) and G1–2 nausea (17.7%). The ORR was 57.3%. Stable disease was observed in 29.1% of patients, with a disease control rate of 86.4%. With a median follow-up of 18 months, the median PFS was 10.0 months (95% confidence interval [CI]: 8.5–11.4), while the median OS was 18.0 months (95% CI: 16.0–19.9). No statistically significant difference was observed between the regimens in terms of ORR, PFS (p = 0.908), and OS (p = 0.832). Conclusion This study shows that with an appropriate design, including reduced doses, vulnerable older patients best tolerate chemotherapy when combined with anti-EGFR antibodies.

Published
2022
Full Text
View/download PDF

14. Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.

Author

Fortis C, Soldini L, Ghezzi S, Colombo S, Tambussi G, Vicenzi E, Gianotti N, Nozza S, Veglia F, Murone M, Lazzarin A, and Poli G

Subjects
Dose-Response Relationship, Drug, HIV Infections blood, HIV Infections metabolism, Humans, Injections, Intravenous, Injections, Subcutaneous, Interleukin-2 adverse effects, Interleukin-2 blood, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, Interleukin-2 therapeutic use, Receptors, Interleukin-2 blood, Tumor Necrosis Factor-alpha analysis
Abstract

HIV-infected individuals with 200-500 CD4(+) T cell/microl were enrolled in a controlled study of three interleukin 2 (IL-2) plus antiretroviral therapy (ART) regimens: (1) continuous intravenous administration of 12 million international units (MIU) of IL-2 followed by subcutaneous high-dose IL-2 (7.5 MIU, twice daily) for 5 days every 8 weeks; (2) high-dose subcutaneous IL-2 for 5 days every 8 weeks; (3) low-dose (3 MIU, twice daily) subcutaneous IL-2 for 5 days every 4 weeks; and (4) ART alone. Serum concentrations of IL-2, soluble IL-2 receptor (sIL-2R), tumor necrosis factor alpha (TNF-alpha), and IL-6 were determined. A progressive decrease over time of the circulating levels of IL-2 was observed in individuals receiving the highest doses of IL-2, but not in those belonging to the low-dose arm. Conversely, increased levels of sIL-2R were observed in all cytokine-treated individuals. The levels of TNF-alpha increased in the high-dose IL-2 regimens, but decreased in individuals receiving low-dose IL-2. IL-2-related toxicity was significantly correlated to the peak IL-2 serum levels, and was substantially lower in those individuals receiving low-dose IL-2. In conclusion, intermittent IL-2 administration causes the elevation of peripheral CD4(+) T cells, but also a profound cytokine response and systemic toxicity. The latter was correlated to the peak serum level of IL-2, but not to those of TNF-alpha and IL-6.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results